IN SITU HYBRIDIZATION - COMPLEMENTARY REAGENTS - ANVISA Registration 10337990033

Access comprehensive regulatory information for IN SITU HYBRIDIZATION - COMPLEMENTARY REAGENTS in Brazil's medical device market through Pure Global AI's free database. This Risk Class I medical device is registered under ANVISA number 10337990033 and manufactured by LEICA BIOSYSTEMS NEWCASTLE LTD. The registration is held by LEICA DO BRASIL IMPORTAÇÃO E COMÉRCIO LTDA. with validity until currently active (VIGENTE).

This page provides complete technical specifications for this device, regulatory compliance details, 4 companies making the same product including AGILENT TECHNOLOGIES SINGAPORE (INTERNATIONAL) PTE LTD., ABBOTT MOLECULAR, and 5 recent registrations in the same technical category. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.